文献速递其他结缔组织病

抗拓扑异构酶抗体对系统性硬化症死亡率和疾病严重程度的性别特异性风险:Leiden CCISS和EUSTAR队列的10年分析

Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts.
PubMed 文献 · Lancet Rheumatol · 2022-01-01

该研究基于Leiden CCISS前瞻性队列和EUSTAR国际队列的10年数据,评估抗拓扑异构酶I抗体(ATA)对系统性硬化症患者死亡、弥漫性皮肤型、间质性肺病和肺动脉高压的性别特异性风险。结果显示ATA阳性男性10年死亡率高于ATA阳性女性(CCISS 30% vs 12%;EUSTAR 33% vs 15%),校正年龄、种族和自身抗体状态后男性仍为全因死亡的最重要危险因素(CCISS HR 2.9,EUSTAR HR 2.6)。

要点

  • ATA阳性男性10年死亡率CCISS为30%、EUSTAR为33%,均高于同队列ATA阳性女性的12%和15%。
  • 校正年龄、种族和自身抗体状态后,男性全因死亡风险CCISS HR 2.9(95%CI 1.5-5.5),EUSTAR HR 2.6(95%CI 2.0-3.4)。
  • 两个队列中ATA表达男性均显著多于女性(CCISS 39/101 vs 67/344;EUSTAR 381/783 vs 1323/3480;均p<0.0001)。

核心结论

  • 男性性别与系统性硬化症死亡率增加之间的关联不能用ATA患病率更高来解释。
  • 仍需针对性别特异性特征对系统性硬化症患者影响开展进一步研究。

研究设计与样本

  • 研究为荷兰Leiden CCISS前瞻性队列(2009年4月1日至2022年1月1日)和国际EUSTAR队列(2004年6月1日至2018年3月28日)的10年分析。
  • 纳入标准为符合2013年ACR-EULAR分类标准的系统性硬化症、有可用自身抗体状态、有可用皮肤亚型分型、至少一次间质性肺病影像学评估、已知疾病发病日期。
  • 按性别和自身抗体状态分为六组:ACA阳性女性、ACA阳性男性、ACA和ATA均阴性女性、ACA和ATA均阴性男性、ATA阳性女性、ATA阳性男性。
  • 采用Kaplan-Meier曲线和Cox比例风险模型,并考虑左截断生存以防止偏倚,因所有患者疾病发病日期(首个非雷诺现象症状)早于队列入组日期。
  • CCISS队列708例中445例(63%)符合条件(男性101例[23%],女性344例[77%]);EUSTAR队列8590例中4263例(50%)符合条件(男性783例[18%],女性3480例[82%])。

主要发现

  • 两个队列中ATA表达男性均显著多于女性:CCISS男性39/101(39%)vs女性67/344(19%),p<0.0001;EUSTAR男性381/783(49%)vs女性1323/3480(38%),p<0.0001。
  • 估计10年生存率显示ATA阳性男性死亡CCISS为30% vs ATA阳性女性12%,EUSTAR为33% vs 15%。
  • 校正年龄、种族和自身抗体状态后,男性仍为全因死亡最重要危险因素:CCISS HR 2.9(95%CI 1.5-5.5),p=0.0018;EUSTAR HR 2.6(95%CI 2.0-3.4),p<0.0001。

关键数值与推荐

  • 系统性硬化症诊断依据2013年ACR-EULAR分类标准。
  • ATA阳性男性10年死亡比例CCISS为30%、EUSTAR为33%;ATA阳性女性分别为12%和15%。
  • 男性全因死亡风险CCISS HR 2.9(95%CI 1.5-5.5,p=0.0018),EUSTAR HR 2.6(95%CI 2.0-3.4,p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出仍需针对性别特异性特征对系统性硬化症患者影响开展进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to evaluate sex-specific risk of anti-topoisomerase I antibodies (ATA) on mortality, diffuse cutaneous systemic sclerosis, interstitial lung disease, and pulmonary hypertension in two cohorts of people with systemic sclerosis. METHODS: This study was a 10-year analysis of the prospective Leiden Combined Care in Systemic Sclerosis (CCISS) cohort in the Netherlands and the international European Scleroderma Trials and Research (EUSTAR) cohort. We included participants with systemic sclerosis according to the 2013 American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) classification criteria; available autoantibody status; available skin subtyping; at least one available radiographic assessment of interstitial lung disease; and with a known date of disease onset. People with systemic sclerosis were categorised in six risk groups by sex and autoantibody status (anti-centromere antibody [ACA]-positive female, ACA-positive male, ACA and ATA-negative female, ACA and ATA-negative male, ATA-positive female, and ATA-positive male). We constructed Kaplan-Meier curves and Cox proportional hazard models, accounting for left-truncated survival to prevent bias because the date of disease onset (first non-Raynaud's symptom) preceded the date of cohort entry for all patients. The primary outcome was all-cause mortality and the secondary outcomes were diffuse cutaneous systemic sclerosis, interstitial lung disease, and pulmonary hypertension. FINDINGS: 445 (63%) of 708 participants between April 1, 2009, and Jan 1, 2022, in CCISS (101 [23%] male and 344 [77%] female) and 4263 (50%) of 8590 between June 1, 2004, and March 28, 2018, in EUSTAR (783 [18%] male and 3480 [82%] female) were eligible for this study. In both cohorts, ATA expression occurred significantly more often in males than in females (39 [39%] of 101 males vs 67 [19%] of 344 females in CCISS; p<0·0001 and 381 [49%] of 783 males vs 1323 [38%] of 3480 females in EUSTAR; p<0·0001). According to estimated survival rates, 30% of ATA-positive males versus 12% of ATA-positive females died in the CCISS cohort and 33% versus 15% died in the EUSTAR cohort within 10 years. After adjustment for age, race, and autoantibody status, male sex remained the most important risk factor for all-cause mortality (HR 2·9 [95% CI 1·5-5·5] in CCISS, p=0·0018; and HR 2·6 [2·0-3·4] in EUSTAR, p<0·0001). INTERPRETATION: We show that the association between male sex and increased mortality in systemic sclerosis cannot be explained by higher ATA prevalence. However, additional research on the effect of sex-specific characteristics on people with systemic sclerosis is required. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Liem SIE, Boonstra M, le Cessie S, et al. Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts. Lancet Rheumatol. 2022. PMID: 38265968. doi:10.1016/S2665-9913(22)00224-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。